Ross Fubini
Independent
Tenure on this board
New nominee
Meeting calendar
DNA · Annual meeting · Thursday, June 11, 2026
Ginkgo Bioworks Holdings Inc
6 nominees · 3 ballot items.
Election of six directors; Ratification of Deloitte & Touche LLP as independent auditors for fiscal year 2026; Advisory (non-binding) approval of executive compensation; and transaction of other business as may properly come before the meeting.
Market cap
$517M
1Y TSR
-21.4%
Board grade
D
Record date
Apr 15, 2026
Filing
DEF 14A
Meeting concluded · Jun 11, 2026
Follow how the vote landed and what changed on Ginkgo Bioworks Holdings Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect six director nominees (Ross Fubini, Christian Henry, Jason Kelly, Sri Kosuri, Reshma Shetty, Harry E. Sloan) to serve until the next annual meeting.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify appointment of Deloitte & Touche LLP as Ginkgo’s independent registered public accounting firm for fiscal year ending December 31, 2026.
More detail
This management proposal asks shareholders to ratify Deloitte & Touche LLP as Ginkgo’s independent registered public accounting firm for fiscal 2026. Management and the Audit Committee selected Deloitte following a request-for-proposal process and due to considerations including Deloitte’s qualifications, independence, and the Audit Committee’s oversight role. The proposal is routine in governance practice and is presented as a matter of good corporate governance to obtain shareholder ratification; the Board recommends a vote FOR, noting that if shareholders do not ratify the selection the Audit Committee will take the result into account when choosing the auditor for 2027 and may solicit proposals in the future.
- 3
Advisory Vote to Approve Executive Compensation
ManagementBoard: FORNon-binding advisory vote to approve the compensation of the named executive officers as disclosed in the proxy statement ("Say-on-Pay").
More detail
This management proposal requests an advisory (non-binding) shareholder vote to approve the company's executive compensation disclosed in the proxy statement. Management and the Compensation Committee argue the compensation program aligns pay with long-term performance, emphasizes equity-based incentives (PSUs and RSUs), and ties compensation to Company-wide cash flow and other metrics. The Board recommends a vote FOR, asserting the program helps attract and retain talent, aligns executives with shareholder interests, and incorporates governance best practices such as independent consultant engagement and clawback policies. The vote is advisory, but the Compensation Committee will consider results when evaluating future compensation decisions; key context includes the 2024 Founder Compensation Program cancellation and replacement with PSUs in 2025, certification of PSU performance in early 2026, and continued focus on cash burn reduction and autonomous labs strategy.
Director elections
Nominees on the ballot6
Independent
Tenure on this board
4.8 yrs
Also a director at
Wave Life Sciences Ltd (WVE)Pacific Biosciences Of California Inc (PACB)
Not independent
Tenure on this board
4.8 yrs
Independent
Tenure on this board
1.7 yrs
Not independent
Tenure on this board
4.8 yrs
Independent
Tenure on this board
5.8 yrs
Also a director at
Draftkings Inc (DKNG)Bold Eagle Acquisition Corp (BEAG)Lionsgate Studios Corp (LION)Infinite Eagle Acquisition Corp (IEAG)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VIKING GLOBAL INVESTORS LP | 5.5% | 3,577,128 | $22M |
| 2 | BAILLIE GIFFORD CO | 3.7% | 2,391,649 | $15M |
| 3 | Erste Asset Management GmbH | 3.0% | 1,947,728 | $11M |
| 4 | BlackRock, Inc. | 3.0% | 1,947,482 | $12M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 1,914,428 | $12M |
| 6 | Anchorage Capital Group, L.L.C. | 2.7% | 1,746,363 | $11M |
| 7 | Legal General Group Plc | 2.5% | 1,653,871 | $10M |
| 8 | STATE STREET CORP | 2.1% | 1,346,659 | $8M |
| 9 | BlackRock, Inc. | 2.0% | 1,332,285 | $8M |
| 10 | FORBES J M CO LLP | 1.6% | 1,028,391 | $6M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Ginkgo Bioworks Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Ginkgo Bioworks Holdings Inc 2026 annual meeting?
- Ginkgo Bioworks Holdings Inc (DNA) holds its 2026 annual shareholder meeting on Thursday, June 11, 2026.
- What is the record date for the Ginkgo Bioworks Holdings Inc 2026 meeting?
- The record date for the Ginkgo Bioworks Holdings Inc 2026 meeting is Wednesday, April 15, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Ginkgo Bioworks Holdings Inc's 2026 meeting?
- The board is presenting 6 director nominees at the Ginkgo Bioworks Holdings Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Ginkgo Bioworks Holdings Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Ginkgo Bioworks Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.